TG Therapeutics Inc (TGTX)

[stockguard]

A new licensing deal has H.C. Wainwright very bullish on TG Therapeutics (TGTX) this morning. They reiterated their Buy rating and price target of $33 a share, more than triple the current trading level of the stock. Wainwright's analyst had this to say about the announced deal:

TG Announces Global License Agreement With Jiangsu Hengrui Medicine for Development of Novel BTK Inhibitors TG licenses novel BTK inhibitors that demonstrate superior selectivity to BTK in comparison to ibrutinib in the preclinical setting. On the morning of January 8, TG Therapeutics announced that it has entered into an exclusive global license agreement with Jiangsu Hengrui Medicine, pursuant to which TG will obtain worldwide rights, excluding Asia but including Japan, for the development of Hengrui's BTK inhibitor program. The program includes TG-1701 and TG-1702, both of which are orally-available, covalently-bound BTK inhibitors.

http://www.analystratings.com/articles/tg-therapeutics-gets-a-buy-rating-from-h-c-wainwright/